Cooperative Agreement UG3DA061495
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$612K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Providence, RI 02903, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $406,451.00 to Ksana Health Inc. to develop and refine the VIRA mobile app platform as an adjunctive treatment for opioid use disorder (OUD). The key products and services to be delivered include: Technical development and user-centered research to extend the VIRA platform's capabilities to provide just-in-time interventions for two types of cues...
The National Institute on Drug Abuse (NIDA) awarded a $2,729,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Rhode Island. The purpose of this 2-year award, with a start date of September 15, 2024, is to rigorously develop and evaluate a mobile health intervention for adults with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during community re-entry after residential OUD treatment. The proposed mobile app...
This Project Grant award, with a total funding amount of $958,629, was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support the real-world adoption of an innovative digital health therapeutic called KIOS, which uses nonlinear control theory to track multiple symptoms (e.g., craving, mood, pain) and deliver personalized, evidence-based intervention strategies to patients with opioid use disorder...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This Project Grant award of $591,032 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Square2 Systems Inc. in Hanover, NH. The funding will support the development of the "COGITO" platform, a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment, and management of substance use disorders and other behavioral health conditions. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,930,360 to evaluate the real-world effectiveness of telehealth-delivered buprenorphine (tele-buprenorphine) for treating opioid use disorder (OUD). The study will use national data from the Veterans Health Administration and Medicaid to compare the effectiveness of tele-buprenorphine to in-person care, including for high-risk and high-need...
The National Institute on Drug Abuse (NIDA) awarded a $643,978 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to See Yourself Health LLC, a woman-owned small business in Beverly, MA. The grant titled "The CHIRON Project: Using Virtual Reality to Prevent Substance Use Disorder in Healthcare Workers Facing Burnout" aims to develop an immersive virtual reality platform that enables healthcare professionals to access confidential peer support, evidence-based...
This Cooperative Agreement award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and validate a novel patient-reported outcome measure of substance-related consequences for use in substance use disorder (SUD) treatment trials. The $352,064 award, effective from August 1, 2025 to July 31, 2027, will be executed by the Mclean Hospital Corporation, a non-profit psychiatric teaching hospital affiliated with...
This federal Project Grant award, with ID R01DA059503, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $1,192,612 grant will fund a 5-year research project by The Miriam Hospital, a non-profit healthcare and research institution in Providence, RI, to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key objectives of this multidisciplinary research...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...